Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Immunotherapy. 2011 Feb;3(2):153-62. doi: 10.2217/imt.10.100.
Ovarian cancer remains the leading cause of death due to gynecologic malignancies. Most patients present with advanced disease at the time of diagnosis. Although many have a good initial response to surgical debulking and platinum-based chemotherapy, relapse is common, with the eventual development of chemotherapy resistance. Innovative treatments are needed in the remission setting to prolong the disease-free interval or prevent recurrence. Abagovomab is a murine monoclonal anti-idiotypic antibody (molecular weight: 165-175 kDa) that functionally imitates the tumor-associated antigen, CA-125. It has been shown to be well tolerated and to induce a sustained immune response in initial Phase I and II clinical trials. An ongoing, double-blind, placebo-controlled, multicenter, Phase III trial (MIMOSA) completed its double-blind period in December 2010 and will compare abagovomab maintenance therapy to placebo, which will definitively determine the efficacy of this immunotherapeutic approach in patients with ovarian cancer.
卵巢癌仍然是妇科恶性肿瘤导致死亡的主要原因。大多数患者在诊断时已处于晚期疾病。尽管许多患者对手术减瘤和铂类为基础的化疗有良好的初始反应，但复发是常见的，最终会出现化疗耐药。在缓解期需要创新的治疗方法来延长无病间期或预防复发。Abagovomab 是一种鼠单克隆抗独特型抗体（分子量：165-175 kDa），在功能上模拟肿瘤相关抗原 CA-125。在最初的 I 期和 II 期临床试验中，它已被证明具有良好的耐受性，并能诱导持续的免疫反应。一项正在进行的、双盲、安慰剂对照、多中心、III 期试验（MIMOSA）已于 2010 年 12 月完成其双盲期，将比较 abagovomab 维持治疗与安慰剂，这将最终确定这种免疫治疗方法在卵巢癌患者中的疗效。
